Celcuity公司今日宣布，其新药Revtorpyk™ (gedatolisib) 已获得美国食品药品监督管理局（FDA）的批准。该药物获准用于治疗激素受体阳性、HER2阴性，且PIK3CA基因呈野生型的局部晚期或转移性乳腺癌患者。此项批准标志着针对这一特定乳腺癌亚型患者群体的一项重要治疗新选择。
Celcuity公司今日宣布，其新药Revtorpyk™ (gedatolisib) 已获得美国食品药品监督管理局（FDA）的批准。该药物获准用于治疗激素受体阳性、HER2阴性，且PIK3CA基因呈野生型的局部晚期或转移性乳腺癌患者。此项批准标志着针对这一特定乳腺癌亚型患者群体的一项重要治疗新选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.